Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1619-1623

  Sader, Helio S ^a   Biedenbach, Douglas J ^a   Paukner, Susanne ^b   Ivezic Schoenfeld, Zrinka ^b   Jonesa, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b Nabriva Therapeutics Inc   (Austria)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BC 3781; LINEZOLID; OXACILLIN; PLEUROMUTILIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CROSS RESISTANCE; DRUG POTENCY; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN STRUCTURE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; DITERPENES; DRUGS, INVESTIGATIONAL; ENTEROCOCCUS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SKIN; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCUS; STREPTOCOCCUS; VANCOMYCIN;

EID: 84857183374     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05789-11     Document Type: Article

References (17)

1. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. 2007. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 28:1047-1053. (Pubitemid 47345264)
2. Bhavnani S, et al. 2011. Pharmacokinetic-pharmacodynamic analysis for efficacy of BC-3781 using new clinical trial endpoints in patients with acute bacterial skin and skin structure infection, abstr. A2-025. Abstr. 51st Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC). American Society for Microbiology, Washington, DC.
3. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th edition. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
5. EUCAST. 2010. Clinical breakpoints-bacteria. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1, April 2010. Available at http://www.eucast.org/clinical-breakpoints/. Accessed 10 June 2010.
6. GlaxoSmithKline. 2007. Altabax package insert. GlaxoSmithKline, Research Triangle Park, NC. Available at http://us.gsk.com/products/assets /us-altabax.pdf.
7. Kavanagh F, Hervey A, Robbins WJ. 1951. Antibiotic substances from basidiomycetes: VIII. Pleurotus Multilus (Fr.) Sacc. and Pleurotus Passeckerianus Pilat. Proc. Natl. Acad. Sci. U. S. A. 37:570-574.
8. Long KS, Hansen LH, Jakobsen L, Vester B. 2006. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob. Agents Chemother. 50:1458-1462.
9. McDougal LK, et al. 2003. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120. (Pubitemid 37429924)
10. Milheirico C, Oliveira DC, de Lencastre H. 2007. Update to the multiplex PCR strategy for assignment of mec element types in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:3374-3377. (Pubitemid 350067556)
11. Moore CL, et al. 2009. Comparative evaluation of epidemiology and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA300 infections causing community- and healthcare-associated infections. Int. J. Antimicrob. Agents 34:148-155.
12. Novak R, Shlaes DM. 2010. The pleuromutilin antibiotics: a new class for human use. Curr. Opin. Investig. Drugs 11:182-191.
13. Poulsen SM, Karlsson M, Johansson LB, Vester B. 2001. The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol. Microbiol. 41:1091-1099. (Pubitemid 36124705)
14. Rubino CM, et al. 2011. Population pharmacokinetic analyses for BC- 3781 using phase 2 data, abstr. A2-024. Abstr. 51st Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC). American Society for Microbiology, Washington, DC.
15. Schlunzen F, Pyetan E, Fucini P, Yonath A, Harms JM. 2004. Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol. Microbiol. 54:1287-1294. (Pubitemid 39578271)
16. Stevens DL, et al. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406. (Pubitemid 41581713)
17. Weinberg JM, Tyring SK. 2010. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J. Drugs Dermatol. 9:1198-1204.